文献速递炎症性肠病

优化英夫利西单药治疗与优化联合治疗在炎症性肠病中疗效相当但药物消耗更高

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-02-19

本研究在149例炎症性肠病患者中比较优化英夫利西单药与联合硫唑嘌呤治疗的临床成功率和药物消耗。两组药物留存率、激素使用及黏膜愈合无显著差异,但单药治疗第1年英夫利西消耗更高且谷浓度更低,硫唑嘌呤停用后差异消失。

要点

  • 优化单药与联合治疗的药物留存率在诱导后、第1年及随访终点均无显著差异。
  • 第1年单药组英夫利西消耗更高(7.6 vs 6.4 mg/kg q8周,P=0.019)且谷浓度更低(1.7 vs 5.0 µg/mL,P=0.012)。
  • 硫唑嘌呤停用后,单药与联合治疗之间的药物消耗和谷浓度差异消失。

核心结论

  • 优化英夫利西单药治疗与联合治疗临床疗效相当,但单药治疗英夫利西消耗显著更高。
  • 硫唑嘌呤停用后,英夫利西节省效应消失。

研究设计与样本

  • 研究纳入149例开始英夫利西治疗并接受强化药物监测辅助治疗优化的炎症性肠病患者,其中克罗恩病94例,溃疡性结肠炎55例。
  • 比较优化单药治疗与联合硫唑嘌呤治疗的临床成功率和英夫利西消耗。

主要发现

  • 药物留存率:优化单药组 vs 联合治疗组在诱导后为96% vs 97%(P=0.73),第1年为90% vs 83%(P=0.23),随访终点为74% vs 75%(P=0.968)。
  • 第1年激素使用:优化单药组5% vs 联合治疗组14%(P=0.08);随访终点黏膜愈合:64% vs 67%(P=0.8)。
  • 第1年英夫利西消耗:优化单药组7.6 mg/kg q8周(IQR 5.9-10.3) vs 联合治疗组6.4 mg/kg q8周(IQR 5.2-8.0),P=0.019。
  • 第1年谷浓度:优化单药组1.7 µg/mL(IQR 0.3-6.6) vs 联合治疗组5.0 µg/mL(IQR 2.5-8.7),P=0.012;药物-谷浓度比值单药组3.9 vs 联合组1.5。
  • 随访终点时硫唑嘌呤已停用中位14个月(IQR 3-33),上述差异消失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative. AIM: To compare the clinical success and infliximab consumption of combination vs optimised monotherapy strategies. METHODS: We studied the clinical success and infliximab consumption of both strategies in 149 patients (94 Crohn's disease; 55 ulcerative colitis) starting infliximab and undergoing intensive drug monitoring assisted treatment optimisation. RESULTS: The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968). Similarly, no differences were observed for steroid use at year 1 (5% vs 14%, P = 0.08) or mucosal healing at the end of follow-up (64% vs 67%, P = 0.8). Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1. At the end of follow-up, when azathioprine had been discontinued for a median of 14 [IQR: 3-33] months, these differences disappeared. CONCLUSIONS: In this study, optimised infliximab monotherapy was as clinically effective as combination therapy but was associated with significantly higher infliximab consumption. The infliximab-sparing effect disappeared after azathioprine withdrawal.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Drobne D, Kurent T, Golob S, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019. PMID: 30784100. doi:10.1111/apt.15179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。